Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy. Cancer Discovery 2016 Jan; 6(1): 45-58.
We describe the first generation screen for new oncogenes and the initial characterization of a novel commonly amplified oncogene, MECP2.
Birkbak NJ, Wang ZC, Kim JY, Ecklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, *Silver DP, *Szallasi Z, *Richardson AL. Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discovery 2012; Apr; 2(4):366-75. (*co-senior authors)
This paper describes the first biomarker of chemotherapy response derived from counting the number of a specific kind of chromosomal abnormality.
Telli ML, Timms K, Reid J , Hennessy B, Mills G, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones J, Lanchbury JS, Hartman A, Garber JE, Ford JM, Silver DP*, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer 2016 Aug; 22(15), 3764–3773. *Corresponding author*
Here we demonstrate the utility of a biomarker of chemotherapy response based upon telomeric allelic imbalance.